ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1518

Predictive Value of Chronic Histologic Changes in Lupus Nephritis

Maria Cuellar-Gutierrez1, Jaime Flores Gouyonnet1, Gabriel Figueroa-Parra2, Marta Casal Moura1, Fernando C. Fervenza1, Andrew C. Hanson3, Cynthia Crowson1, Sanjeev Sethi1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Mayo Clinic, Rochester

Meeting: ACR Convergence 2024

Keywords: Lupus nephritis, Renal, risk assessment, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in lupus nephritis (LN).

Methods: LN patients from the Mayo Clinic between 1992 and 2023 were included. The earliest kidney biopsy was the index date. Follow-up was until July 2023, death or loss follow-up. Biopsy reports were reviewed by a nephropathologist, and chronic lesions were reclassified (glomerulosclerosis [GS], interstitial fibrosis [IF], tubular atrophy [TA], arteriosclerosis [AE], and fibrous crescents [FC]). The outcomes were proteinuria < 500 mg/day and complete renal response (CRR) within 1 year, defined as proteinuria < 500 mg/day with eGFR decrease of < 20%, end-stage kidney disease (ESKD), and death. We used stratified multivariable proportional hazards regression adjusted for sex and age. P-values < 0.05 were statistically significant.

Results: We included 307 patients (median age, 34 years; 75% female; median follow-up, 11 years). The majority had Class III or IV. FC was present in 4.9% of patients, and AE was present in 12% of patients.
At 1 year, 47.5% had proteinuria < 500 mg/day and 43.4% CRR. Those with grade 2-3 of GS (HR 0.21 [0.09, 0.48] and grade 2-3 IFTA (HR 0.14 [0.05, 0.39] were less likely to achieve proteinuria < 500 mg/day. Grade 2-3 of GS (HR 0.19 [0.08, 0.48]) and grade 2-3 IFTA (HR 0.16 [0.06, 0.44] were also less likely to achieve CRR.
Similarly, those with AE were less likely to have proteinuria < 500 mg/day (HR 0.44 [0.21, 0.91]  for mg/day or CRR (HR 0.37 [0.16, 0.84]).
During follow-up, 33 patients died, and 60 developed ESKD. No variables were associated with mortality. Grade 2-3 GS (HR 9.28 [4.91, 17.54], grade 2-3 IFTA (HR 20.10 [10.08, 40.08]), and AE (HR 3.56 [1.87, 6.78]), were associated with an increased ESKD.

Conclusion: GS, IFTA, and AE are independently associated with outcomes in LN. FC is a rare finding in LN. The MCCS included all the chronic histologic elements associated with outcomes in LN.

Supporting image 1

Table. Hazard ratios of proteinuria<500mg/day_1 year, CRR_1 year, ESRD, and death for different variables of interest.


Disclosures: M. Cuellar-Gutierrez: None; J. Flores Gouyonnet: None; G. Figueroa-Parra: None; M. Casal Moura: None; F. Fervenza: None; A. Hanson: None; C. Crowson: None; S. Sethi: None; A. Duarte-Garcia: None.

To cite this abstract in AMA style:

Cuellar-Gutierrez M, Flores Gouyonnet J, Figueroa-Parra G, Casal Moura M, Fervenza F, Hanson A, Crowson C, Sethi S, Duarte-Garcia A. Predictive Value of Chronic Histologic Changes in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/predictive-value-of-chronic-histologic-changes-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-value-of-chronic-histologic-changes-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology